drugset / Trial / NCT04321161

Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

NCT04321161

Phase 0 Completed 10 enrolled University of Freiburg
NaSingle-groupOpen-labelTreatment

Summary

In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.

Timeline

Start
2020-02-25
Primary completion
2020-03-18
Completion
2020-03-18

Drugs

EvaluationDrugModalityDoseRoute
Subject sodium bicarbonate Diagnostic / imaging agent 1 g